Association of Dynamic Changes In Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 May 31

PMID 34054853

Citations 20

Authors

Yuzhong Chen

Shaodi Wen

Jingwei Xia

Xiaoyue Du

Yuan Wu

Banzhou Pan

Wei Zhu

Bo Shen

Affiliations

Soon will be listed here.

Abstract

Background: PD-1 inhibitors have been routinely used in the treatment of advanced non-small cell lung cancer (NSCLC), and have demonstrated to significantly improve survivorship when combining with other conventional therapies, such as chemotherapy and anti-angiogenesis therapy. PD-L1 is the most commonly used biomarker to select benefiting groups, while not all patients with high PD-L1 expression benefit from immunotherapy. Therefore, identifying other prognostic and predictive biomarkers, including peripheral blood indexes, is essential.

Methods: We retrospectively collected medical records and hematological data of 151 patients with advanced NSCLC treated with PD-1 inhibitor-based combination therapy in our hospital. The peripheral blood indexes of interest were NLR, PLR, PAR, Hb, LDH, CEA, and NSE. The association between peripheral blood indexes and treatment responses or survival outcomes was examined by multivariable logistic regression and Cox regression, respectively.

Results: The decreased CEA at week 6 (OR = 4.209, 95%CI: 1.287-13.758) or 12 (OR = 7.267, 95%CI: 1.508-35.006) post-treatment was related to a higher disease control rate. The decrease or NLR at week 6 (OR = 3.081, 95%CI: 1.464-6.483) or 12 (OR = 3.304, 95%CI: 1.560-7.001) post-treatment, or CEA at week 12 post-treatment (OR = 2.469, 95%CI: 1.134-5.375), was associated with a higher objective response rate. Patients whose NLR (HR = 0.610, 95%CI: 0.411-0.907) or CEA (HR = 0.477, 95%CI: 0.320-0.710) decreased at week 6 post-treatment tended to have longer progression-free survival, and similar results were found in those with decreased NLR (HR = 0.587, 95%CI: 0.388-0.886) or CEA (HR = 0.406, 95%CI: 0.270-0.609) at week 12 post-treatment. Patients whose CEA (HR = 0.543, 95%CI: 0.339-0.871) or NSE (HR = 0.619, 95%CI: 0.386-0.994) decreased after 6 weeks post-treatment appeared to have longer overall survival, and the same was found for those whoseCEA (HR = 0.620, 95%CI: 0.390-0.986) or NSE (HR = 0.578, 95%CI: 0.353-0.947) was decreased at 12 weeks after treatment.

Conclusion: Post-treatment NLR, CEA and NSE changes are suggestive indicators for the prognosis of NSCLC patients after immunotherapy.

Citing Articles

Predicting prognosis of locally advanced esophageal squamous cell carcinoma through early changes in neutrophil-to-lymphocyte ratio following neoadjuvant immunochemotherapy.

Chen Y, Huang S, Chen R, Lan Z, Gao Z, Li Z J Thorac Dis. 2025; 16(12):8230-8239.

PMID: 39831247 PMC: 11740040. DOI: 10.21037/jtd-24-1115.

The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.

Xie Y, Sun H, Shan L, Ma X, Sun Q, Liu F Front Oncol. 2025; 14:1454709.

PMID: 39741972 PMC: 11685080. DOI: 10.3389/fonc.2024.1454709.

Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.

Yang Y, Wang Z, Xin D, Guan L, Yue B, Zhang Q Front Immunol. 2024; 15:1468342.

PMID: 39512347 PMC: 11540680. DOI: 10.3389/fimmu.2024.1468342.

Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes.

Wang Y, Sun C, Liu M, Xu P, Li Y, Zhang Y Front Immunol. 2024; 15:1424393.

PMID: 39211047 PMC: 11357960. DOI: 10.3389/fimmu.2024.1424393.

Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.

Zhai W, Zhang C, Duan F, Xie J, Dai S, Lin Y Front Immunol. 2024; 15:1422717.

PMID: 39108262 PMC: 11300317. DOI: 10.3389/fimmu.2024.1422717.

References

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim Y, Tomii K . Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018; 119:14-20. DOI: 10.1016/j.lungcan.2018.02.017. View

Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K . Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study. Lung Cancer. 2019; 134:59-65. DOI: 10.1016/j.lungcan.2019.05.033. View

Alex F, Alfredo A . Promising predictors of checkpoint inhibitor response in NSCLC. Expert Rev Anticancer Ther. 2020; 20(11):931-937. DOI: 10.1080/14737140.2020.1816173. View

Gregory A, Houghton A . Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011; 71(7):2411-6. DOI: 10.1158/0008-5472.CAN-10-2583. View

Zhou J, Donaubauer A, Frey B, Becker I, Rutzner S, Eckstein M . Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer. 2021; 9(2). PMC: 7888377. DOI: 10.1136/jitc-2020-001845. View

Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2019; 15(2):288-293. PMC: 7244187. DOI: 10.1016/j.jtho.2019.10.002. View

Russo A, Russano M, Franchina T, Migliorino M, Aprile G, Mansueto G . Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Adv Ther. 2020; 37(3):1145-1155. DOI: 10.1007/s12325-020-01229-w. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D . Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother. 2020; 69(12):2513-2522. PMC: 11027462. DOI: 10.1007/s00262-020-02637-1. View

10.

Suh K, Kim S, Kim Y, Kim M, Keam B, Kim T . Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2017; 67(3):459-470. PMC: 11028357. DOI: 10.1007/s00262-017-2092-x. View

11.

Guo M, Sun T, Zhao Z, Ming L . Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer. Ann Thorac Cardiovasc Surg. 2020; 27(2):84-90. PMC: 8058543. DOI: 10.5761/atcs.oa.20-00090. View

12.

Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino M, Sparano F . Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021; 152:165-173. DOI: 10.1016/j.lungcan.2020.12.027. View

13.

Jiang M, Peng W, Pu X, Chen B, Li J, Xu F . Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. Front Oncol. 2020; 10:913. PMC: 7339928. DOI: 10.3389/fonc.2020.00913. View

14.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

15.

Valero C, Lee M, Hoen D, Weiss K, Kelly D, Adusumilli P . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021; 12(1):729. PMC: 7851155. DOI: 10.1038/s41467-021-20935-9. View

16.

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

17.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

18.

Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K . Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Thorac Oncol. 2017; 13(1):97-105. DOI: 10.1016/j.jtho.2017.10.030. View

19.

Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q . Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2020; 12:1758835920970049. PMC: 7649885. DOI: 10.1177/1758835920970049. View

20.

Takada K, Takamori S, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M . Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer. 2020; 145:18-26. DOI: 10.1016/j.lungcan.2020.04.034. View